Brief: Celcuity Announces First Patient Dosed In Phase 1b/2 CELC-G-201 Clinical Trial Of Gedatolisib
22/02/2024 21:33
Feb 22 (Reuters) - Celcuity Inc CELC.O :
* CELCUITY ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B/2
CELC-G-201
CLINICAL TRIAL OF GEDATOLISIB FOR THE TREATMENT OF METASTATIC
CASTRATION RESISTANT PROSTATE CANCER
Source text for Eikon: ID:nGNX1J0J45
Further company coverage: CELC.O
(Reuters.Briefs@thomsonreuters.com)